

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072870 A2

(51) International Patent Classification⁷: C12Q

(21) International Application Number: PCT/US02/07546

(22) International Filing Date: 13 March 2002 (13.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/805,326 13 March 2001 (13.03.2001) US

(71) Applicant: **WHATMAN, INC.** [US/US]; 200 Wells Avenue, Newton, MA 02459-3304 (US).

(72) Inventors: **BURGOYNE, Leigh, Alexander**; 18 Broughton Avenue, A-5062 Mitcham (AU). **SMITH, Martin**; 127 Browne Street, Brookline, MA 02146 (US). **BUTT, Neil, James**; 15 Petworth Street, Cambridge CB2 2LY (GB).

(74) Agents: **HAZZARD, Lisa, Swiszczy et al.**; Edwards & Angell, LLP, P.O. Box 9169, Boston, MA 02209 (US).

(81) Designated States (*national*): AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

--- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DRY SOLID MEDIUM FOR STORAGE AND ANALYSIS OF GENETIC MATERIAL

(57) Abstract: The present invention provides for device for obtaining and storing genetic material. The device has a support and a head portion. The head portion is composed of a solid matrix for sorbing genetic material and a preserving mechanism for the protection of genetic material from degradation. Additionally, the present invention provides for a method of storing a sample of genetic material onto the swab device. In the preferred embodiment, the present invention utilizes polyester material as the solid matrix.



WO 02/072870 A2

DRY SOLID MEDIUM FOR STORAGE AND ANALYSIS OF GENETIC MATERIAL

5

FIELD OF THE INVENTION

The field of the present invention pertains to a dry solid medium and method
10 for collection of genetic material in a form suitable for storage and/or subsequent
analysis. Specifically, the present invention provides for a sampling device and
method for collecting genetic material through the use of the dry solid medium. The
invention further provides for analysis of stored genetic material using methods that
are suited for automated analyzing systems.

15

BACKGROUND

Blood containing genetic material to be analyzed has typically been
transported from the place of removal from a human or animal to the place of analysis
20 as purified genetic material, liquid whole blood, frozen whole blood or whole blood
dried onto paper. All of the methods have disadvantages. Transport of genetic
material in blood as dried, purified genetic material is most desirable, but it requires a
high standard of technical assistance to be available at the place of removal from the
human or animal. When technical assistance is not available at the place of removal,
25 whole blood or other unpurified samples are usually sent to a central facility where
the genetic material is purified.

Transport of liquid whole blood often involves the need for sterility of
collection. Under some circumstances, this is extremely inconvenient, for example,
where the sample is a heel-prick taken from an infant. The transport of liquid whole
30 blood or frozen blood also demands temperature control and an appropriate transport
system other than the regular postal system. This is true even before considering
concerns about hygiene. In addition, problems with pathogens associated with whole
blood, such as the HIV virus, generally rule out the transport of any potentially
infectious liquid or frozen sample except under proper and expensive supervision.

Blood dried on filter paper is a proven alternative to the above procedures and it has been shown that genetic material can be extracted and isolated from dried whole blood spots in a form and in sufficient quantities for use in DNA analysis. McCabe, E.R.B., et al., "DNA Microextraction From Blood Spots on Filter Paper Blotters: Potential Screening Applications to Newborn Screening," Hum. Genet. 75:213-216 (1987). But, this procedure still suffers from a number of disadvantages. For example, typically, there has been no deliberate and rapid destruction of blood associated pathogens. This creates a potential hazard for blood handling personnel. In addition, usually, there has not been deliberate inhibition of the processes that degrade the genetic material other than occurring by desiccation. However, slow desiccation, or a small degree of re-hydration under conditions of relatively high humidity, will allow the growth of DNA or RNA destroying microflora. Moreover, even in the presence of a bacteriostatic agent of the type that does not denature proteins, there are conditions that permit enzymatic-autolytic breakdown of the genetic material and some nonenzymatic breakdown of the genetic material. (Enzymatic-autolytic breakdown refers to the process whereby dying or damaged tissues, of either human, animal or parasite cells, activate enzymes that degrade their own components). Furthermore, there is typically considerable difficulty desorbing very high molecular weight DNA or RNA from paper, if this is required. Surface adsorption effects can cause losses of genetic material that may cause the preferential loss of the least degraded, i.e. the most desired class of DNA or RNA molecules.

Thus, there is a need for a safe, convenient and minimally labor intensive means for storage of a genetic material to be analyzed that is contained in a liquid sample.

However, even if a sample of genetic material is collected in a safe, convenient and reliable form for storage and subsequent analysis, there are also logistic problems, which arise when there are many different types of analysis to be performed on a collected sample. For example, polymerase chain reaction (PCR) analysis requires a different primer-pair for each specific analysis to be performed. Obviously, the problems tend to further increase when multiple samples are submitted for analysis.

Present methods for in-situ processing based on the use of oligonucleotide primers, for example, PCR, rely on the stored genetic material being heated and cooled in reaction mixtures that have primers added to them at the time of beginning

temperature cycling. In many types of analysis of genetic material, it is the primers that determine the particular specificity of a reaction. Because there is usually a primer pair for each conceivable type of analysis, there are an extremely large number of possible primers (for example, all the sequences within the genes of humans, animals and all other living organisms including the pathogens of humans and animals). Thus, in any centralized facility that receives multiple samples for analysis of genetic material using, for example, oligonucleotide primers, the logistic problems can be immense.

Automation of analysis of genetic material allows for increased numbers of samples to be processed more efficiently. However, automation of the analysis of genetic material still requires the automated system to have completely separate delivery devices for each different set of primers. Otherwise, the cross-contamination that may occur will be impossible to control.

Thus, in general, if reactions like PCR are to be carried out at a centralized location using automated systems and using presently known methods, the range of different sequences which can be analyzed at one time will be restricted by the physical problems of keeping a clean delivery system of pipettes, etc., or by the molecular problems inherent in using mixtures of diverse primers. Clearly, circumvention of this restriction would be advantageous for analyzing multiple samples of genetic material for different genetic sequences.

Finally, samples can be taken from various surfaces and areas to test samples for particular substances such as antigens or genetic material. Currently, common methods can involve utilizing a swab or swab-like device. Generally, once the sample is obtained the sample is transferred to another medium to perform any subsequent analysis. In most cases, the swab is capable of being used on any surface, including, but not limited to skin, wounds, flesh, body orifices such as the mouth, and any other living or nonliving surface. Most swabs used and known to those of skill in the art have the basic components of a narrow rod support in combination with a collecting medium positioned and attached adjacent to the support.

SUMMARY OF THE INVENTION

The present invention provides a safe, convenient and minimally labor intensive apparatus and method for storage of a genetic material that is contained in a

liquid medium. The present invention specifically provides for a sampling device and method for collecting genetic material through the use of a dry solid medium. The invention further provides for storage of genetic material in such a way as to allow for simplified analysis of one or more samples of genetic material using automated
5 systems.

The invention provides a dry solid medium for storage of a sample of genetic material. The dry solid medium of the invention is composed of a solid matrix and a composition which when applied to the dry solid medium protects against degradation of genetic material stored on the dry solid medium. The dry solid medium further
10 provides for inactivation of microorganisms, including those that may be pathogenic to humans.

The composition of the dry solid medium includes a weak base, a chelating agent, and anionic detergent and optionally, uric acid or a urate salt.

According to the invention, genetic material stored on the dry solid medium
15 may be analyzed using methods known in the art, for example, polymerized chain reaction (PCR), ligase chain reaction (LCR), reverse transcriptase initiated PCR, DNA or RNA hybridization techniques including restriction fragment length polymorphism (RFLP) and other techniques using genetic or DNA or RNA probes, genomic sequencing, enzymic assays, affinity labeling, methods of detection using
20 labels or antibodies and other similar methods.

Genetic material stored on the dry solid medium of the invention may be analyzed in situ or after removal from the dry solid medium.

Another embodiment of the invention provides a dry solid medium for storage of a sample of genetic material and includes a component that is functional in the
25 subsequent analysis to be performed on the stored sample of genetic material. According to the invention, components for subsequent analysis which may be included with a sample of genetic material include, for example, nucleotide sequences such as PCR primers, target sequence stabilizers, genetic probes, primers for genetic sequencing or sets of oligonucleotide substrates for LCR analysis.

30 The invention also provides methods for using the dry solid media of the invention. In one embodiment, the invention provides a method for storing a sample of genetic material on the dry solid medium in a substantially non-degraded form.

The invention further provides a method for storing a sample of genetic material and subsequently analyzing the stored sample of genetic material. According

to this embodiment of the invention, the stored genetic material is preferably washed to remove any proteins or hemoglobin associated with a sample of genetic material or to remove any component of the composition of the dry solid medium which may inhibit subsequent analysis of the genetic material. The invention provides for the
5 stored genetic material to be washed using either an aqueous or a non-aqueous washing system.

The aqueous and non-aqueous washing systems used to wash a sample of genetic material prior to analyzing the genetic material provide for removing protein, hemoglobin or components of the composition of the dry solid medium without
10 substantially affecting the stored genetic material or any component included on the dry solid medium for subsequent analysis of the genetic material. In addition, the aqueous and non-aqueous wash systems of the invention may be used to wash genetic material that is stored, for example, on a solid matrix which does not have sorbed to it the DNA protecting composition of the invention.

15 The non-aqueous wash system of the invention includes contacting a sample of genetic material stored on the dry solid medium of the invention with a herein-described single-phase phenol solution. The single-phase phenol solution is then removed from the dry solid medium containing a sample of genetic material and the dry solid medium containing a sample of genetic material is then contacted with an
20 aqueous alcohol wash solution. The aqueous alcohol wash solution is removed and the dry solid medium containing the sample of genetic material may further be washed with an aqueous ionic solution. The washed sample of genetic material may then be analyzed by methods recited above.

A sample of genetic material stored on a dry solid medium of the invention
25 may also be analyzed using standard enzymic tests used, for example, to detect phenylketonuria (PKU) or galactosemia after neutralizing the effects of protein denaturing components of the dry solid medium using, for example, a converter solution.

The dry solid medium and the dry solid medium including components for
30 subsequent analysis is particularly useful for analysis of a genetic sample using automated systems.

A further embodiment of the present invention is the use of the dry solid medium as a swab device used to obtain and gather genetic material samples.

Additionally, the present invention provides for a method of collecting genetic material samples utilizing the swab device.

BRIEF DESCRIPTION OF THE DRAWINGS

5

Other advantages of the present invention will be readily appreciated, as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:

Figure 1, Photograph of ethidium bromide stained gel of PCR amplified DNA from blood samples stored on a dry solid medium of the invention.

Figure 2, Photograph of ethidium bromide stained gel of PCR amplified DNA from blood samples stored on a dry solid medium of the invention which included oligonucleotide primers for PCR analysis.

Figure 3, Photograph of ethidium bromide stained gel of Eco R1 digestion of DNA from human blood stored on the dry solid medium of the invention.

Figure 4, Photograph of ethidium bromide stained gel of genomic DNA material. Lane 1 is a 1 kb marker, lane 2 is "traditional" genomic DNA material, and the remaining 12 lanes are samples amplified from PET-FTA swabs.

Figure 5, Multiplex PCR profile from gDNA isolated using an FTA-coated PET filter membrane swab wherein 10 µl of eluted gDNA is used per reaction.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a dry solid medium for collection of genetic material in a form suitable for storage and subsequent analysis. The invention further provides methods for subsequently analyzing the collected genetic material. The dry solid medium and methods of use, disclosed herein, provide a safe, convenient and reliable means for storing samples of genetic material in a manner that provides reliable accuracy of analytical results. Moreover, the invention provides for enhanced convenience and efficiency when multiple samples are analyzed using automated systems, for example, at a centralized analyzing facility.

In several places throughout the present specification guidance is provided through lists of examples. The inventors wish to make clear that in each instance, the

recited lists serve only as representation groups. It is not meant, however, that the lists are exclusive.

As used herein, the phrase "genetic material" (GM) means either or both deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). According to the invention,
5 a sample of GM is collected on the dry solid medium by removing the sample from a source and applying the sample to the herein-described dry solid medium. Methods for removing a sample of genetic material from a source are known in the art. For example, a sample of genetic material in blood may be removed from a human or animal source by venipuncture and the sample then applied to the dry solid medium of
10 the invention.

As used herein a "sample of genetic material" or "sample of GM" includes a liquid having dissolved, suspended, mixed or otherwise contained therein, either or both DNA or RNA, cells which contain either or both DNA or RNA or cell components which contain either or both DNA or RNA. Once the sample of GM is
15 applied to the dry solid medium, the liquid tends to evaporate (evaporation may be enhanced by a warm air dryer) leaving the DNA and/or RNA entrained to the dry solid medium in a dry form. The GM entrained to the dry solid medium in "dry form" may be purified DNA and/or RNA, semipurified DNA and/or RNA or DNA and/or RNA remaining in cells.

20 The sample of GM, which is applied to the dry solid medium, may be derived from any source. This includes, for example, physiological/pathological body liquids (e.g., secretions, excretions, exudates and transudates) or cell suspensions (e.g., blood, lymph, synovial fluid, semen, saliva containing buccal cells, skin scrapings, hair root cells, etc.) of humans and animals; physiological/pathological liquids or cell
25 suspensions of plants; liquid products, extracts or suspensions of bacteria, fungi, plasmids, viruses, etc.; liquid products, protozoa, spirochetes, etc.; liquid extracts or homogenates of human or animal body tissues (e.g., bone, liver, kidney, etc.); media from DNA or RNA synthesis; mixtures of chemically or biochemically synthesized DNA or RNA; and any other source in which DNA and/or RNA is or can be in a
30 liquid medium. Preferably, the liquid containing the GM evaporates after applying the sample to the dry solid medium leaving GM in dry form prior to subsequent analysis.

The dry solid medium of the invention provides for storage and/or subsequent analysis of the stored sample of GM. The dry solid medium is composed of a solid matrix having sorbed thereto a composition that can protect against degradation of the

GM stored on the solid medium. The composition can also cause inactivation of microorganisms which may be associated with a sample of GM and which may be potentially pathogenic to human handlers of the stored sample of GM.

5 A solid medium and a composition sorbed to a solid matrix are disclosed in U.S. patent application S/N 08/159,104 that has been incorporated herein by reference.

As used herein, the term "storing," "storage," "stored" and other derivatives of "store," when referring to GM in dry form entrained to the dry solid medium means the preservation of GM in a form suitable for subsequent analysis and which has not
10 undergone substantial degradation. The time period for which GM may be stored according to the invention may be as short as the time necessary to transport a sample of GM from the place of collection of the sample to the place where subsequent analysis is to be performed. The condition under which the sample of GM may be stored on the dry solid medium of the invention varies. Typically, samples are stored
15 at temperatures from -20°C to 40°C. In addition, stored samples may optionally be stored in dry or desiccated conditions or under an inert atmosphere. Storage may be for a few minutes up to many years. Preferably, storage occurs for about 10 minutes up to 10 years.

As used herein, the term "swab," "swab device," and any other similar
20 derivatives of "device" means an apparatus having a head portion made of a dry solid medium that can collect, store and preserve genetic material applied thereto. The preferred embodiment has a narrow rod or cylindrical-shaped support or handle in combination with the dry solid medium that is positioned adjacent to the support. The dry solid medium is attached to the support in a manner including, but not limited to,
25 wrapping the dry solid medium around the support, gluing support to the dry solid medium, completely integrating the dry solid medium onto the support, and any other similar methods known to those of skill in the art. The head portion has the dry solid medium shaped or formed into, but not limited to, a filter, a mesh, woven bulb, and any other similar shape or form known to those of skill in the art.

30 In another embodiment of the invention, the dry solid medium may further include a component which is functional in the subsequent analysis to be performed on the stored GM. Subsequent analysis which may be performed on a sample of GM stored on the dry solid medium includes analysis methods known in the art, for example, polymerase chain reaction (PCR), ligase chain reaction (LCR), reverse

transcriptase initiated PCR, DNA or RNA hybridization techniques including restriction fragment length polymorphism (RFLP) and other techniques using genetic or DNA or RNA probes, genomic sequencing, enzymatic assays, affinity labeling, method of detection using labels or antibodies and other similar methods. In a preferred embodiment, the dry solid medium of the invention is a suitable medium for storage of components for subsequent analysis, which are included on the dry solid medium. In addition, the inventors recognize that many new analytical and diagnostic methods may be developed in the future for which the dry solid medium and method of the invention may be equally useful and which would fall within the spirit and scope of the claims appended hereto.

In the case of stored RNA, particularly unstable RNA, components for subsequent analysis that may be included may also provide protection against RNA degradation. This includes RNase inhibitors and inactivators, proteins and organic moieties that stabilize RNA or prevent its degradation.

Once the GM has been collected on the dry solid medium, it may be encased in a protective material, for example, a plastic film, which may further protect against GM degradation during storage. Subsequent analysis of the GM stored on the solid medium of the invention may be performed in situ on the solid medium or, alternatively, the GM may first be removed from the solid medium prior to subsequent analysis.

I. THE DRY SOLID MEDIUM

The dry solid medium of the invention includes a composition sorbed to a solid matrix. As used herein, the term "sorb" means that the composition of the invention is absorbed, adsorbed or otherwise incorporated into or onto the solid matrix in such a way as not to be readily removed from the matrix unless subjected to conditions which are intentionally or inadvertently performed to remove the sorbed composition from the solid matrix.

A solid matrix suitable for the dry solid medium and method of the invention includes any material to which the composition will sorb and which does not inhibit storage or subsequent analysis of the GM applied to the dry solid medium. This includes flat dry matrices or a matrix combined with a binder to form a pellet or tablet to which composition is sorbed. In one preferred embodiment, the solid matrix is of a porous nature to provide entrainment of the GM onto the dry solid medium. As used

herein the term "entrain" means that during storage the GM is bound to the dry solid medium without substantial reliance on ionic, covalent or van der waals interactions. A solid matrix suitable for this purpose includes, but is not limited to, a matrix which is cellulose based (e.g., cellulose, nitrocellulose or carboxymethylcellulose papers),
5 hydrophilic polymers including synthetic hydrophilic polymers (e.g., polyester, polyamide, carbohydrate polymers), polytetrafluoroethylene (Empore™, 3M, St. Paul, Minnesota), fiberglass and porous ceramics.

GM may also be collected on a solid matrix that lacks the below-described composition of the invention. In addition, a component for subsequent analysis of a
10 sample of GM may also be included on a solid matrix that lacks the composition of the invention. Furthermore, hemoglobin or proteins associated with a sample of GM may be removed from a sample of GM stored on a solid matrix which does or does not include a component for subsequent analysis of the stored GM using an aqueous or non-aqueous (e.g., below-described single phase phenol wash) extraction
15 procedure. However, by using only a solid matrix for storage, the GM protecting and pathogen inactivation effects of the composition of the invention obviously will not be available to the GM or components for subsequent analysis.

To form the dry solid medium of the invention, a composition that protects against degradation of GM is sorbed to the solid matrix. As used herein, the phrase
20 "protects against degradation of GM," means that the dry solid medium of the invention maintains the stored GM in a substantially non-degraded form. This provides a sample of GM suitable for many different types of subsequent analytical procedures. Protection against degradation of GM may include protection against substantial damaging of GM due to GM damaging events such as that caused by
25 chemical or biological means including action of bacteria, viruses, free radicals, nucleases, ultraviolet radiation, oxidizing agents and acidic agents (e.g., pollutants in the atmosphere).

The composition sorbed to the solid matrix to form the dry solid medium of the invention may include one or more of a weak base, a chelating agent, or any
30 anionic detergent or surfactant. In addition, the composition sorbed to the dry solid medium may also include uric acid or a urate salt.

As used herein, the "weak base" of the composition may be a Lewis base that has a pH of about 6 to 10, preferably about pH 8 to 9.5. One function of the weak base is to act as a buffer to maintain a composition pH of about 6 to 10, preferably about

pH 8.0 to , for example, pH 8.6. Hence, a weak base suitable for the composition of the invention may, in conjunction with other components of the composition, provide a composition pH of 6 to 10, preferably, about pH 8.0 to 9.5. Suitable weak bases according to the invention include organic and inorganic bases. Suitable
5 inorganic weak bases include, for example, an alkali metal carbonate, bicarbonate, phosphate or borate (e.g., sodium, lithium, or potassium carbonate). Suitable organic weak bases include, for example, tris-hydroxymethyl amino methane (Tris), ethanolamine, triethanolamine and glycine and alkaline salts of organic acids (e.g., trisodium citrate). A preferred organic weak base is a weak monovalent organic base,
10 for example, Tris. The Tris may be either a free base or a salt, for example, a carbonate salt.

Although the inventors do not wish to be limited to a single theory, it is believed that the weak base may provide a variety of functions, including protecting the GM from degradation. In addition to providing a buffer system, it is also believed
15 that the weak base can act to ensure proper action of the below-described chelating agent in binding divalent metal ions. In addition, the weak base may also prevent the action of acid nucleases that may not be completely dependent on divalent metal ions for functioning.

The composition of the dry solid medium can also include a chelating agent.
20 According to the invention, a preferred chelating agent is a strong chelating agent. By "strong" chelating agent it is meant that the agent binds multivalent metal ions with a comparable or better affinity than ethylene diamine tetraacetic acid (EDTA). A preferred chelating agent according to the invention is EDTA. Although the inventors do not wish to be limited to a particular theory, it is believed that one function of the
25 chelating agent of the invention is to bind divalent ions which if present with the stored GM may partake in causing damage to the GM. Ions that may be chelated by the chelating agent include divalent active metal ions, for example, magnesium and calcium, and transition metal ions, for example, iron. Both calcium and magnesium are known to promote GM degradation by acting as co-factors for enzymes that may
30 destroy GM (e.g., most know nucleases). In addition, transition metal ions, such as iron, may readily undergo oxidation and reduction and damage nucleic acids by the production of free radicals or by direct oxidation.

The composition of the dry solid medium can further include an anionic detergent or surfactant. As used herein, the terms "surfactant" and "detergent" are

synonymous and may be used interchangeably. Although not wishing to be limited to a single theory, it is believed that the anionic surfactant of the invention functions to denature non-GM compounds, for example, proteins, which are associated with the stored GM. Accordingly, denaturation of protein is one function of the anionic
5 surfactant. According to the invention, any anionic surfactant that binds to and denatures proteins may be suitable for the invention. A preferred anionic detergent is a strong anionic detergent. As used herein, a "strong" anionic detergent includes a hydrocarbon moiety, aliphatic or aromatic, containing one or more anionic groups. Particularly preferred anionic detergents suitable for the invention include sodium
10 dodecyl sulphate (SDS) and sodium lauryl sarcosinate (SLS). In a preferred embodiment, the anionic detergent of the invention causes inactivation of most microorganisms that have protein or lipids in their outer membranes or capsids, for example, fungi, bacteria or viruses. This includes microorganisms that may be pathogenic to humans and are present in a sample of GM.

15 Inactivation of a microorganism is believed to result from destruction of the secondary structure of its external proteins, internal proteins and any protein containing membranes necessary for viability. The inventors recognize that the anionic detergent may not inactivate some forms of organisms, for example, highly resistant bacterial spores and extremely stable enteric virions. Moreover, the inventors
20 further recognize that while it may be desirable to inactivate pathogenic microorganisms, the GM of a microorganism associated with the stored sample of GM is also amenable for storage on dry solid medium of the invention. This allows for storage and/or subsequent analysis of the GM of a microorganism associated with a stored sample of GM.

25 The composition invention may optionally include a uric acid or urate salt. According to the invention, the longer the period of time for which the GM is to be stored the more likely that uric acid or a urate salt may need to be included in the composition sorbed to the solid matrix. However, even if the GM is only to be stored for a matter of minutes, it may still be desirable to incorporate uric acid or urate salts
30 into the composition.

While the inventors do not wish to be limited to any single theory, it is believed that the uric acid or urate salt may provide many functions. For example, the uric acid or urate salt may be converted to allantoin in acting as a free radical trap that preferentially accepts free radicals that would otherwise damage the nucleotide

guanine. The free radicals are believed to be generated by spontaneous oxidation of thio groups that are present, for example, in denatured serum protein of blood. Free radicals may also be generated due to oxidation or reduction of iron in blood. Because uric acid is a weak acid, it may also function as a component of the buffering system provided by the weak base as discussed above. In addition, the uric acid and urate salt may act as an erodible surface in that it is sparingly soluble so that a DNA sample dried onto its crystals will be released as the urate beneath erodes. Hence, the uric acid or urate salts may also provide for easy removal of a stored sample of GM if in situ processing is not desired.

Furthermore, after the sample of GM is applied to the dry solid medium, the dry solid medium with the applied sample of GM may be encased in a protective material, for example, a plastic film, which may further protect against degradation of stored GM. Examples of plastic films that are suitable according to the invention include polystyrene, polyethylene, polypropylene and other suitable lamination plastics. Encasing the dry solid medium in a protective material may be accomplished by method known in the art. One simple method for encasing the dry solid medium in a plastic film is to put the dry solid medium into a container, e.g., a polyethylene bag, which is of sufficient size to hold the dry solid medium such that when a plastic film in liquid form is added to the container all parts of the dry solid medium will be coated by the liquid. The plastic film, in liquid form, is added to the container to coat the dry solid medium. The liquid plastic film is allowed to dry to provide a plastic film coating which encases the dry solid medium. Prior to analysis, the plastic film is removed from the dry solid medium using methods known in the art, for example, dissolving with organic solvents such as chloroform or mechanical stripping.

The inventors further note that a dry solid medium including components for subsequent analysis (discussed below), with an applied sample of GM, may also be encased in a protective material as described above.

II. SUBSEQUENT ANALYSIS OF GENETIC MATERIAL STORED ON THE DRY SOLID MEDIUM

As used herein, "subsequent analysis" includes any analysis that may be performed on a sample of GM stored on the dry solid medium. The GM stored on the dry solid medium may be analyzed in vitro. The GM may first be removed from the dry solid medium prior to analysis. The sample of GM may be subjected to chemical, biochemical or biological analysis. Examples of subsequent analysis which may be

performed on samples of GM stored on the dry solid medium include polymerase chain reaction (PCR), ligase chain reaction (LCR), reverse transcriptase initiated PCR, DNA or RNA hybridization techniques including restriction fragment length polymorphism (RFLP) and other techniques using genetic or DNA or RNA probes, or genomic sequencing. In addition, diagnostic procedures presently performed on whole blood samples, for example, the Guthrie test for phenyl-ketonuria (PKU) or enzymatic tests, for example, galactosemia may be performed on blood samples stored on the dry solid medium of the invention after first neutralizing the effects of protein denaturing components of the dry solid medium, for example, using a "converter solution." GM stored on the dry solid medium of the invention may also serve as a template for subsequent analysis of the GM using PCR methods. This includes PCR using DNA or RNA as a template. When RNA is the GM to be analyzed, the RNA may serve as a template using reverse transcriptase initiated PCR. The DNA sequence produced from the RNA template may then serve as a template for further PCR amplification.

If the sample of GM is in whole blood, prior to analysis by PCR, LCR, RFLP, reverse transcriptase initiated PCR, genetic probing or other technique, hemoglobin or proteins associated with the GM are preferably removed from the sample of GM stored on the dry solid medium. Hemoglobin and/or proteins associated with the GM may be removed using methods known in the art, for example, aqueous or non-aqueous extraction procedures. In addition, some components of the composition of the invention (e.g., anionic detergent) are preferably removed, using aqueous or non-aqueous extraction procedures, prior to subsequent analysis.

In one preferred embodiment, hemoglobin, blood proteins or other proteins associated with a sample of GM may be removed using non-aqueous extraction procedures, for example, the below-described single-phase phenol wash method. In addition, the single phase phenol wash may be followed with the below-described ionic aqueous alcohol wash to provide ions necessary for subsequent PCR, LCR or similar analysis of GM stored on the dry solid medium.

Methods for PCR, LCR, reverse transcriptase initiated PCR, DNA or RNA hybridization, genomic sequencing, and other methods of subsequent analysis are known in the art.

In another embodiment of the invention, a sample of GM associated with proteins or hemoglobin that is stored on the dry solid medium of the invention may be

removed using aqueous extraction. One such aqueous extraction procedure uses aqueous SDS and mercaptoethanol. Specifically, the sample of GM stored on the dry solid medium of the invention, with or without components for subsequent analysis, is washed with an alkaline solution of aqueous 6% SDS at pH 8.5 to 9.0 which contains
5 the thiol, for example, 20mM 2-mercaptoethanol or dithiothreitol. The GM is then washed with isopropanol to remove substantially all remaining anionic detergent (e.g., using the aqueous alcohol wash solution described below for the single-phase phenol wash).

As will be apparent to those skilled in the art, in situ subsequent analysis of the
10 GM stored on the dry solid medium of the invention with or without components for subsequent analysis is of particular benefit in automated systems. As used herein, an "automated system" includes "automatic fluid delivery systems." According to the invention, "automatic fluid delivery systems" include hand-held and robotic fluid delivery systems. Typically, automatic fluid delivery systems are devices that
15 dispense and remove fluid reagents to and from individual wells of multi-well reaction plates. Hand-held automatic fluid delivery systems comprise a single plunger handle with multiple fluid aspirating and dispensing ends to simultaneously aspirate and dispense fluid of a fluid reaction system from single or multiple reaction vessels simultaneously. Robotic automatic fluid delivery systems are computer operated
20 rather than hand-held and include such products as, for example, BIOMEK 2000 (Beckman Instruments, Fullerton, CA), Zymark Benchmate (Zymark, Hopkinton, MA) and ROSYS PLATO (Rapperswil, Switzerland). Automated fluid delivery systems are also discussed in U.S. Serial No. 08/320,041 that is incorporated herein by reference.

25

A. SINGLE-PHASE PHENOL WASH

Another aspect of the present invention provides a non-aqueous extraction method for removing hemoglobin and/or proteins associated with a stored sample of GM. According to the invention, hemoglobin and proteins may be removed from a
30 stored sample of GM using a single-phase phenol wash. Preferably, the single-phase phenol wash also removes components of the composition of the invention (e.g., anionic detergent). The single-phase phenol wash is performed by contacting a single-phase phenol solution with the dry solid medium having applied thereto a sample of GM. The single-phase phenol wash is removed for the dry solid medium

containing a sample of GM and the dry solid medium is then contacted with an aqueous alcohol wash. The aqueous alcohol wash is then removed. If the sample of GM is to be analyzed by PCR, LCR or other method that relies on ions, the sample of GM may then be contacted with an ionic aqueous alcohol wash prior to PCR analysis.

- 5 As previously noted, a non-aqueous wash system such as the single-phase phenol wash or an aqueous wash system may also be used to wash a sample of GM stored on a solid matrix, with or without included components for subsequent analysis, which does not have the composition of the invention sorbed thereto.

The single-phase phenol wash provides for removing proteins and/or
10 hemoglobin or components of the composition of the dry solid medium that may affect the subsequent treatment to be performed on the GM stored on the dry solid medium without affecting the stored GM. Unlike prior art methods, the present wash system does not require two phase separations (aqueous and organic phase) during processing and tends not to dissolve GM present in blood. The single-phase wash is
15 also amenable to automated systems.

The single-phase phenol wash is also disclosed in U.S. Patent Application S/N 08/159,104. The wash includes two solutions, referred to below as "single-phase phenol solution" (solution A) and "aqueous alcohol wash solution" (solution B). A third solution, "ionic aqueous alcohol wash solution" (solution C), may be used,
20 after the single-phase phenol wash if the sample of GM is to be analyzed using a method which requires additional ions for example, PCR and LCR.

Solution A: The single-phase phenol solution (also referred to as water unsaturated phenol wash) includes phenol and hydroxyquinoline saturated with Tris-acetate and
25 mercaptoethanol. Preferably, 50 grams (gm) of phenol is combined with 120 milligram (mg) of 8-hydroxyquinolone saturated with 10 milliliter (ml) of 1.0 molar (M) Tris-acetate at pH 6.0 to 9.0, preferably pH 8.0, and 1.0 ml 2-mercaptoethanol. After saturation by shaking at a temperature of about 0°C to 20°C, preferably 0°C to 4°C the aqueous phase is removed and discarded.

30

Solution B: The aqueous wash solution utilizes any C₂-C₅ alcohol, such as isopropanol or n-propanol, or any other similar water miscible solvent combined with an acetate salt or similar organic soluble salt which provides a pH of about 7.0 to 9.0,

preferably about pH 7.8. In a preferred embodiment 75% by volume isopropanol is combined with 25% by volume of 0.1 M potassium acetate at a pH of about 7.8.

Solution C: The ionic aqueous wash solution is a wash solution which provides
5 appropriate ions, for example, magnesium, manganese, sodium, protamine, tris and
similar ions which may be useful in a subsequent analysis procedure. For PCR
analysis, magnesium is preferred. Accordingly, the ionic alcohol wash solution
utilizes any C₂-C₅ alcohol, such as isopropanol and n-propanol, or any other similar
water miscible solvent combined with an acetate salt or similar organic soluble salt
10 which provides a pH of about 6.0 to 8.5, preferably about pH 7.8. In a preferred
embodiment for magnesium ions, 75% by volume isopropanol is combined with 25%
by volume of 0.01 M magnesium acetate at a pH of about 7.5.

According to the invention, a sample of GM associated with hemoglobin
and/or protein which is stored on the dry solid medium is contacted with solution A
15 for about 15 minutes to about 3 hours, preferably about 1.5 to about 2 hours, at a
temperature which is greater than 37°C, preferably about 45-65°C, more preferably
about 50°C. The temperature at which the sample of GM is contacted with solution A
is not critical if the dry solid medium of the invention does not also include a
component for subsequent analysis, such as a primer, which is discussed below. The
20 solution A is then removed. Preferably, the sample of GM is then quickly washed 1-4
times, for a few seconds each time with fresh solution A.

After removal of solution A, the sample of GM is washed, for a few seconds,
1-4 times with solution B. Preferably, the solution B washes are at about 10°C to
25°C. If solution C is to be used, after solution B is removed, solution C is applied to
25 the sample of GM for about 1-60 minutes, preferably about 30 minutes, at a
temperature of about 10°C to 25°C. The solution C is removed and the sample of GM
on the dry solid medium is dried.

Generally, the single-phase phenol wash of the invention provides a
substantially protein and/or hemoglobin free GM that provides a very convenient
30 starting point for a variety of analytical procedures based on nucleic acids. The use of
the single-phase phenol wash and ionic aqueous alcohol wash is further described in
the Examples.

According to the invention, the single-phase phenol wash may be used to
provide a substantially protein/hemoglobin free sample of GM stored on any solid

system. Moreover, as described below, the single-phase phenol wash is of particular benefit when a solid storage system incorporates components for subsequent analysis such as primers. Hence, the single phase phenol wash is useful to remove proteins and/or hemoglobin from a sample of GM stored on a storage medium regardless of whether or not the storage medium incorporates the GM protecting composition of the invention and regardless of whether or not the storage medium includes components necessary for subsequent analysis.

**B. DRY SOLID MEDIUM INCLUDING COMPONENTS
FOR SUBSEQUENT ANALYSIS OF GENETIC MATERIAL**

In another embodiment of the invention, the dry solid medium includes components for subsequent analysis of a stored sample of GM. As previously stated "subsequent analysis" means any analysis which may be performed on a sample of GM stored on the dry solid medium. This includes chemical, biochemical or biological analysis. Examples of subsequent analysis which may be performed on samples of GM stored on the dry solid medium include PCR, LCR, reverse transcriptase initiated PCR, DNA or RNA hybridization techniques including RFLP and other techniques using genetic or DNA or RNA probes, genomic sequencing, enzymic assays, affinity labeling, method of detection using labels or antibodies and other methods known in the art.

As used herein, "components for subsequent analysis of a stored sample of GM" includes a molecule, compound, reagent, or other component that may be functional in analyzing, or preserving for analysis, a sample of GM, or analysis of some other component stored with the GM on the dry solid medium. In some instances, subsequent analysis of some other component stored with the GM on the dry solid medium. In some instances, subsequent analysis will involve an analytical method that is used to establish the absence or presence of a particular genetic sequence. The genetic sequence to be analyzed is termed a "target sequence." The target sequence or other region of a sample of genetic material may serve as a "template" for PCR amplification.

One or more components may be included on the dry solid medium. The component(s) included on the dry solid medium is dependent on the particular analysis to be performed on the sample of GM. The advantage of including a component functional in the subsequent analysis of a sample of GM is readily apparent in situations where large numbers of samples of GM are simultaneously

analyzed using automated systems. An example of a component that may be included on a dry solid medium is a "nucleotide sequence."

As used herein, nucleotide sequence includes a primer, (e.g., a PCR primer, a primer for reverse transcriptase initiated PCR), sets of oligonucleotide substrates for LCR, DNA or RNA probe, oligonucleotides used in genetic sequencing, or target
5 sequence stabilizer.

As used herein, a "primer" means one pair of oligonucleotides, each of which is capable of annealing to a complementary nucleic acid sequence in a sample of GM, and which are oriented so that each primer will prime the synthesis of a strand of
10 DNA (or conceivably, a strand of RNA) containing a sequence complimentary to the other oligonucleotide. For some applications, it is desirable that the sequence of the oligonucleotide and its complimentary sequence are predetermined. In other applications, the sequence may be unknown. A plurality of degenerate primers or primers with sequences predicted to bind to the
15 complimentary sequence may be used. The primer-pair may be used to amplify a pair of complimentary sequences and the sequence between the two complimentary sequences of known or unknown size. In addition, the primer may be used to amplify a template that is initially double-stranded DNA or RNA, as well as single-stranded DNA or RNA. For a single-stranded template, it is understood that the sequence
20 complimentary to one of the oligonucleotides will be synthesized by elongation of the first primer as it is annealed to its complementary sequence.

Primers for PCR or for reverse transcriptase initiated PCR may be present as a primer-pair, as is usual, or there may be only one primer as may be the case with genomic-sequencing or some protocols for reverse transcriptase initiated PCR.

25 In another embodiment of the invention, a component for subsequent analysis may be a nucleotide sequence referred to as a "target sequence stabilizer." A target sequence stabilizer may be beneficial for enhancing storage of an unstable single strand RNA or DNA stored as a sample of GM on the dry solid medium. According to this embodiment, a "target sequence stabilizer" is a nucleotide sequence which may be
30 complimentary to an entire region of RNA or DNA which is to be analyzed. As is known in the art, many single strand RNAs are unstable and vulnerable to degradation by low levels of omnipresent RNases. However, the inventors believe that by including a target sequence stabilizer on the dry solid medium, the target sequence stabilizer binds to the single strand RNA (or DNA) sample and the "hybrid" formed is

less vulnerable to degradation. For example, it is known in the art that double-stranded RNA/DNA hybrids are highly resistant to the common RNases. The RNA or DNA annealed to the target sequence stabilizer may then be further analyzed using methods known in the art, for example, LCR or combinations of LCR and reverse transcriptase initiated PCR.

Therefore, according to the invention, components for subsequent analysis of a stored sample of GM includes components which function in subsequent analysis of a sample of GM as well as provide further protection of a stored sample of GM such that the GM is available, in non-degraded form, for subsequent analysis. The inclusion of a nucleotide sequence on the dry solid medium provide significant advantages for simplifying subsequent analysis of GM by, for example, automated PCR systems. In addition, selection of appropriate nucleotide sequences may provide additional protection from degradation of GM material such as unstable RNA.

Other components for subsequent analysis of stored GM that may be included in the dry solid medium of the invention are, for example, genetic probes or oligonucleotide or polynucleotide sequences with labels of diverse types. Labels may include a fluorescent chemical group, radioactive isotope, chemical binding agent (e.g., biotin), antigens or enzymes.

PCR amplification of a stored sample of GM, for example, blood DNA, is greatly simplified using the dry solid medium of the invention including a nucleotide sequence such as a primer. Furthermore, utilizing the single-phase phenol wash of the invention to remove proteins and/or hemoglobin associated with a sample of GM on a dry solid medium which includes a nucleotide sequence, provides for insubstantial loss of the included nucleotide sequence. By "insubstantial" it is meant that the wash, when completed, has not caused sufficient loss of primer to prevent PCR, LCR, reverse transcriptase initiated PCR, probing, etc. Hence, because both the nucleotide sequence and sample of GM remain entrained to the dry solid medium during the washing procedure, in situ processing is possible. This provides a significant advantage for GM analysis using automated systems.

In the case of PCR amplification, for example, by including a primer necessary for amplifying a specific DNA or RNA gene sequence, multiple samples containing different primers may be analyzed using a single PCR reaction mixture. Typically, only one mixture of PCR enzyme and nucleotides to all vials is necessary. Moreover, even if different primers included with different GM samples require

variation in reaction conditions such as magnesium ions and/or pH, these variations can be accommodated with only two additional pump or pipette systems to deliver inexpensive salts and buffers that will cover most contingencies.

The components for subsequent analysis are preferably included on the dry solid medium before subsequent treatment of the GM. Various permutations for inclusion of the components are possible. For example, the components may be added and mixed with the composition of the dry solid medium prior to application of the composition to the solid matrix. Also, the primers may be added to the solid matrix simultaneously with the composition. Alternatively, the composition of the invention maybe applied to the solid matrix and the primers applied subsequently. In another alternative, a sample of GM may be applied to the dry solid medium and a component applied to the dry solid medium after collection of the sample of GM but before removing any hemoglobin or protein associated with the GM sample. It is also foreseeable that a component may be added to the dry solid medium after removing protein and/or hemoglobin but before subsequent analysis.

Thus, the invention provides for novel and previously impractical strategies to be made feasible by a dry solid medium including a component for subsequent analysis in combination with methods that allow for co-processing the component with the stored GM.

C. INCLUSION OF MULTIPLE NUCLEOTIDE SEQUENCES ON A SINGLE DRY SOLID MEDIUM

The dry solid medium of the invention may also be identified or referred to as a card. A card may be prepared in such a manner as to provide different components for subsequent analysis at different locations on a single card. When the component for subsequent analysis is a nucleotide sequence, multiple different nucleotide sequences for priming amplification or stabilizing different target sequences may be stored on one card. As used herein, "multiple" means greater than one. For example, a single sample of GM to be analyzed may be stored on a single card, which is about 1mm to 5mm square. Therefore, a card, which is about 5 cm X 10 cm, could be divided, for example, into 200 individual samples. Each individual 5 mm square could hold a different nucleotide sequence. Accordingly, a single 5 cm X 10 cm card could provide for subsequent analysis using 200 different nucleotide sequences.

In a preferred embodiment, a nucleotide sequence included on a card for subsequent analysis is a primer. According to this embodiment, a dry solid medium card may incorporate all or many of the primers for a particular application on a single card. For example, one application may be to screen for various target sequences, in a single GM sample, which are all involved in a particular genetic disease. Hence, an unlimited range of pre-made and pre-labeled sample-receiving cards may be held at a collection center ready for samples of GM such as blood. These cards, including primers, may be labeled, packaged and sold for particular categories of usage and put together in defined-purpose folios (e.g., a card for standard penitentiary purposes or a card screening for various diseases of genetic origin). Moreover, the inclusion of a primer on the card allows the dry solid medium to be employed in a variety of different fields and still be conveniently processed together at one centralized, unspecialized center for automated analysis. This will allow the automated system to use one basal mixture of enzyme, and possibly buffer, to simultaneously amplify all target sequences for which primers are present on one type of card. As previously noted, the potential variations in ions and pH can be handled through a variety of ways, for example, separate delivery pumps or the use of the newer pellet-delivery of magnesium or other substances in wax.

III SWAB DEVICE:

The swab device of the present invention utilizes the dry solid medium having the properties disclosed herein. As described in more detail in Example 6, the swab device and the preferred embodiment disclosed therein is used to obtain, store, and analyze various genetic material samples obtained from biological and non-biological fluid samples. This embodiment includes a head portion having a dry solid matrix with the properties of sorbing, storing and preserving the genetic material placed on the dry solid matrix therein. There are numerous types of materials that compose the dry solid medium. The preferred embodiment utilizes polyester. Other suitable materials of the dry solid medium include, but are not limited to, cellulose based material, hydrophilic polymers, synthetic hydrophilic polymers, polyamide, carbohydrate polymers, polytetrafluoroethylene, fiberglass, glass, porous ceramics and any other similar materials known to those of skill in the art.

The swab device additionally has a solid support in combination with the dry solid medium. The solid support allows for the safe handling of the dry solid matrix to prevent any kind of contamination of the dry solid medium. The support can be made

of any material including, but not limited to, plastic, wood, metal, fiberglass and any other similar solid materials known to those of skill in the art. Additionally, the support can be permanently or removeably attached to the dry solid medium through any mechanism known to those of skill in the art. Attachment mechanisms include, but are not limited to, glue, thread, stitching, wrapping the dry solid medium around the support, encasing the dry solid medium, and through any other similar methods known to those of skill in the art.

The swab device can be used in any number of clinical and non-clinical settings. Additionally, the swab device can obtain samples from numerous organic or inorganic, and living or nonliving surfaces. The swab device is safe to be used inside living organisms to swab samples from the inside of flesh wounds, inside of body orifices, and from any part of the human body.

There is a wide range of liquids and biological samples that the present invention can be used to collect. These liquids and samples include, but are not limited to, buccal fluids, cerebrospinal fluid, feces, plasma, blood, lymphatic fluids, urine, suspension of cells or viruses, serum samples, and any other similar biological fluid samples known to those of skill in the art.

EXAMPLES

20

EXAMPLE 1 *In situ* PCR Amplification of Blood DNA Stored on Dry Solid Medium

A sample of blood DNA stored on the dry solid medium of the invention was amplified in situ by the polymerase chain reaction (PCR) technique. The dry solid medium used in this Example was cellulose based paper having sorbed thereto a composition comprising, per sq. cm of paper, 2 micromols uric acid, 8 micromols tris (free base), 0.5 micromols EDTA and 1 mg SDS. The stored blood was washed and suitable ions added prior to PCR amplification.

1.1 **Single-Phase Phenol Wash**

30 **A. Materials**

Solution A: Single-phase phenol wash solution. A suitable mixture is phenol, 50 gm containing 120 mg of 8-hydroxyquinoline that has been saturated with 10 ml of 1.0 M tris-acetate pH 8.0 and 1.0 ml 2-mercaptoethanol. After

saturation by shaking at room temperature, the aqueous phase is thoroughly removed and discarded.

Solution B: Aqueous alcohol wash solution. 75% v/v

Isopropanol, 25% v/v 0.1 M potassium acetate at pH 7.8.

5 Solution C: Ionic aqueous wash solution. 75% v/v

Isopropanol, 25% v/v 0.01 M magnesium acetate.

B. Method

All steps are preferably carried out in a single tube made of a suitable phenol
10 resistant material, e.g. polyethylene.

1. Removal of protein: a 5mm x 5mm square of blood impregnated dry solid medium was treated with 1 ml of solution A, for approximately 1.5 hours at 45°C (since no primers were present, this temperature and time is not critical). The solution A was then aspirated to waste and the paper square quickly washed three
15 times with 0.25 ml of solution A. Each wash was for only a few seconds and was immediately aspirated to waste.

2. Removal of phenol and addition of suitable ions: the dry solid medium from step (a) above was rapidly washed three times with 1 ml of solution B. Washes were at room temperature and were simple additions followed by aspiration to waste.
20 The paper was then washed for 20 minutes at room temperature with solution C. (This is to saturate the GM on the paper with magnesium ions and remove the last of the phenol). The solution C is aspirated to waste and the dry solid medium was solvent-dried with one wash of pure isopropanol and then vacuum dried.

The washed dry solid medium was relatively quite white without any obvious
25 remnants of the red-brown color of blood. It was then used in a PCR reaction mix.

1.2 Amplification of DNA on Dry Solid Medium

The washed sample on dry solid medium described above has been shown to be a suitable substrate for DNA polymerase chain reaction (PCR) amplification of DNA.

30 A. Materials

1. Specimens

Extracted DNA: 10 ml of blood was removed from a male volunteer using standard protocols.

Dry solid medium: Blood samples from the same volunteer

were applied directly to the dry solid medium with subsequent single-phase phenol washing as described above. The dry solid medium was cut into about 1 mm x 1 mm pieces for use in PCR reactions.

5 2. Targets for Amplification

Target No. 1: Region of exon 2 of the n-Ras proto-oncogene on chromosome 1. The primers used are:

R1: 5' TGA CTG AGT ACA AAC TGG TGG TG 3' (SEQ ID N0:1)

10 R2: 5' CTC TAT GGT GGG ATC ATA TTC A 3' (SEQ ID NO: 2).
The amplified DNA fragment obtained with these primers is 110bp in size.

Target No. 2: A male specific Y chromosome repeat sequence. The primers are:

15 007: 5' TGG GCT GGA ATG GAA AGG AAT GCA AAC 3'
 (SEQ ID N0:3) and

008: 5' TCC ATT CGA TTC CAT TTT TTT CGA GAA 3'
 (SEQ ID N0:4).

20 The amplified DNA fragment obtained with these primers is 124 bp in size.

Target No. 3: A male specific Y chromosome repeat sequence. The primers used are:

004: 5' GAA TGT ATT AGA ATG TAA TGA ACT TTA 3'
 (SEQ ID N0:5) and

25 006: 5' TTC CAT TCC ATT CCA TTC CTT TCC TTT 3'
 (SEQ ID N0:6).

The amplified DNA fragment obtained with these primers is 250 bp in size.

B. Method

30 1. PCR Protocol

Extracted DNA (1 µg) or about 1 mm x 1 mm fragments of washed dry solid medium containing a sample of blood DNA were placed into 0.5ml Eppendorf tubes and made to 25 µl in PCR reaction

mixture consisting of:

67 mM Tris HCl (pH 8.8 @ 25° C)

16.6 mM (NH₄)₂ SO₄

2.0 mM MgCl₂

5 0.01 % (w/v) gelatin

0.1 mM deoxynucleotides (dATP, dTTP, dCTP,
dGTP)

0.25 µg of each primer (for respective target).

0.25 U of Taq DNA polymerase.

10 2. The amplification conditions

The mixture was overlaid with 25 µl of light mineral oil and DNA amplification was performed by 30 cycles of amplification on a Perkin Elmer - Cetus "thermal cycler". The first cycle consisted of:

DNA denaturation 6 min. @ 94° C

15 Primer - DNA annealing 1 min. @ 55° C

Taq DNA polymerase extension 1 min. @ 75° C

followed by 29 cycles as above except DNA denaturation was for 1 minute @ 94°C and the extension time on the last cycle was 10 minutes @ 72°C before cooling the reaction mixture to 4°C.

20 1.3 **Results**

After amplification, 10 µl aliquots of PCR mixture were analyzed by electrophoresis on 15% (w/v) polyacrylamide gels. Amplified target DNA was visualized by UV illumination of the ethidium bromide stained gel. An analysis of the products from PCR amplification of extracted blood DNA and blood DNA stored on dry solid medium are shown in Figure 1, as follows:

Lanes 1-3: Target No. 1, lane 1: 1 µg DNA, lane 2: 1mm² filter, lane 3: control (no DNA);

Lanes 4-5: Target No. 2, lane 4: 1 µg DNA, lane 5: mm² filter; Lane 6: control (no DNA);

30 Lanes 7-9: Target No. 3, lane 7: 1 µg DNA; lane 8: 1 mm² filter, lane 9: control (no DNA);

Lane S: DNA size markers (pUC19/HpaII digest).

The results shown in Figure 1 clearly demonstrate that the DNA has not been changed in any way as a result of its storage on the dry solid medium of the invention, and that it can be used in situ as described herein.

EXAMPLE 2 **PCR Reactions on DNA Stored on Dry Solid Medium Including Primers**

5

PCR analysis was performed on dry solid medium including primers added to the dry solid medium prior to the collection of a sample of blood DNA.

2.1 **Genetic Material**

10

A. **Materials**

1. **DNA Templates**

15

For preparing samples of genetic material containing DNA, 3 µl of human blood was applied to a 3 mm square sample of dry solid medium, and the blood was allowed to dry. Unless otherwise indicated, this 3 mm square was then used in each PCR reaction. 3 µl of blood corresponds to approximately 250 nanograms of white-cell DNA. In addition, a control sample of purified human DNA in free solution was amplified using PCR.

2. **Primers**

20

Two synthetic oligonucleotide primers derived from the human Class II HLA gene, DQ-alpha, were used in the experiments. Their sequences are:

5' GTGCTGCAGGTGAACTTGTACCAG 3' (SEQ ID N0:7)

5' CACGGATCCGGTAGCAGCGGTAGAGTTC 3' (SEQ ID N0:8)

25

The size of the PCR product expected using the two primers is 262 bp. Each primer was stored as a stock solution at a concentration of 50 ng/µl. When added to the dry solid medium prior to processing, 150 ng of both primers was added to the 3 mm square of dry solid medium. The primers were always used together at equal concentrations.

2.2 **Single-Phase Phenol Wash**

30

Solution A: Single-phase phenol solution. 50 g of phenol, containing 120 mg of 8-hydroxyquinoline, was saturated with 10 ml of 1.0 M Tris-acetate pH 8.0 and 1.0 ml of 2-β-mercaptoethanol. After saturation at between 0°C and 4°C, the aqueous phase was thoroughly removed and discarded.

Solution B: Aqueous alcohol wash solution. 75% v/v isopropanol, 25% v/v 0.1 M potassium acetate, pH 7.8.

Solution C: Ionic aqueous wash solution. 75% v/v isopropanol, 25% v/v 0.01 M magnesium acetate.

5 **B. Method**

1. **Washing the Dry Solid Medium**

Samples of genetic material stored on the dry solid medium including a primer were processed by first washing the medium with 200 µl of Solution A for two hours at either 37°C or 50°C, followed by two quick rinses of the aqueous phase with
10 Solution A. The medium was next rinsed three times for five minutes each with 200 µl of Solution B at room temperature. The medium was then washed with 200 µl of Solution C for 20 minutes at room temperature and then dried under vacuum. (The wash times were all in excess. In practice, shorter times may be used. The effectiveness of the washes may be monitored by observing loss of color: (1) the
15 hemoglobin; and (2) the hydroxyquinoline.)

2.3 **PCR Protocol**

A. **Materials**

1. **The Example PCR Mix 50 µl.**

The following mixture was placed on washed dry solid medium
20 containing a sample of blood before heat-cycling:

67 mM tris-HCl, (pH 8.8 @ 25°C)
16.6 mM (NH₄)₂ SO₄ 0.2 mg/ml gelatin
0.2 mg/ml gelatin
0.45% Triton X-100
25 2.0 mM MgCl₂
0.2mM each of dATP, dTTP, dCTP, dGTP
2.5 units Taq polymerase.

Template blood DNA was on dry solid medium or purified human DNA as free solution. (50 ng template added when in free solution.)

30 As shown in table 1, primers were included with the dry solid medium and/or in free solution. (100 ng each primer if added as free solution.)

B. **Methods**

1. **The Amplification Conditions**

4 minutes @ 94°C (start conditions)

1 minute @ 94°C

40 seconds @ 50°C (32 cycles)

1 minute @ 72°C

5 4°C (soak-end conditions)

The expected product is a 242 bp segment of the human class-II HLA gene, DQ-alpha.

2. Electrophoresis Conditions

Electrophoresis was in 1 % agarose, 0.045 M tris, 0.045 M Boric acid, 1 mM
10 EDTA, pH 8.0, 1.5 hours at 8.5 volts/cm.

C. Results

A 3 mm x 3 mm primer-loaded dry solid medium were taken. 3 µl of freshly collected human blood from one donor was placed on all dry solid medium samples and allowed to dry. It was then stored at room temperature for 7 days.

15 The squares of dry solid medium were then washed using the single-phase phenol wash and all media-squares then dropped into PCR mixes either with or without added primers. There were thus trials in which the primers were added to the medium before loading blood to the medium, after loading blood to the medium, and to the final PCR mix (see Table 1).

20 After the cycling 8 µl samples of each reaction mix were electrophoresed with Promega PCR marker mix (Promega Corp., Madison, Wisconsin). (Bands at 1000 bp, 750 bp, 500 bp, 300, 150, 50). The gel was stained with ethidium bromide and the product bands photographed (see Figure 2).

Four samples were processed with the single-phase phenol wash taking place
25 at 37°C, and four samples were processed with the single-phase phenol wash taking place at 50°C. Subsequent processing steps and PCR reaction conditions for the two sets of samples were identical. Figure 2 shows that extractions performed at 37°C generated bands of the predicted size, and whose intensities varied (lanes 1-4), while extractions performed at 50°C yielded intense bands of the predicted size (lanes 5-8).

30 To show that the PCR products on DNA recovered from the dry solid medium were specific and corresponded to the expected PCR product, PCR reactions were performed on human DNA purified using standard methods (Figure 2, lane 12), or using no DNA (Figure 2, lane 13). No product was observed if no exogenous DNA

was added to the reaction (Figure 2, lane 13), and the product obtained with purified DNA comigrated with the PCR product obtained from processed samples of medium (Figure 2, compare lanes 11 and 12).

Two additional sets of samples were then extracted at 37°C. To one reaction
5 primers were added to the dry solid medium after the blood. To a second reaction primers were likewise added to the dry solid medium after the blood, and additional primers were added just prior to the beginning of the PCR reaction. The results of this experiment are shown in Figure 2, lanes 9 and 10, respectively. Lane 9 reveals that the DNA on the dry solid medium generated a PCR product of the expected size when
10 primers are added to the dry solid medium after the collection of the blood sample. A more intense PCR product of the expected size was obtained when primers were added just prior to performing the PCR reaction (compare lanes 9 and 10). The results of these experiments are summarized in Table 1.

Table 1. Experimental Conditions of PCR Reactions on DNA Stored on Dry Solid Medium

| Source of Template DNA | Time of Addition of Primers | Phenol Wash Temperature | Lanes in Fig. 2 | Mean Results of PCR |
|--|-----------------------------|-------------------------|-----------------|---------------------|
| Human blood on washed dry solid medium | A | 37° | 1-4 | ++ |
| " | A | 50° | 5-8 | ++++ |
| " | A | 50° | 11 | ++++ |
| Purified human DNA in solution | D | N/A | 12 | ++++ |
| No DNA | D | N/A | 13 | - |
| Human blood on washed dry solid medium | B | 37° | 9 | +++ |
| " | C | 37° | 10 | ++++ |

5 KEY:

| | | | |
|----|------|---|--|
| | A | = | Primers included on dry solid medium before collection of blood sample. |
| | B | = | Primers included on dry solid medium after collection of blood on the medium. |
| 10 | C | = | Primers included on dry solid medium after collection of blood on the dry solid medium, and additional primers added just prior to PCR reaction. |
| | D | = | Primers added just prior to PCR reaction. |
| 15 | N/A | = | Not applicable. |
| | ++++ | = | Intense bands. |
| | +++ | = | Moderately intense bands. |
| | ++ | = | Moderate bands. |
| | + | = | Weak bands. |

20

In summary, the use of the dry solid medium containing primers is clearly practical, it opens a window of technique that makes large-scale PCR analysis much

more practical and amenable to less skilled labor, and opens potential new applications, with unstable templates.

EXAMPLE 3: ***In situ Digestion of Stored Blood with
Restriction Endonuclease Eco R1.***

To determine if samples of blood DNA stored on a cellulose-based dry solid medium were digestible in situ with restriction endonucleases, and thus suitable for procedures such as RFLP analysis, samples of blood were collected on cellulose-based dry solid medium, washed with single-phase phenol wash and digested with the restriction enzyme Eco R1. In this experiment, samples of blood were stored on the dry solid medium for as long as 18 months prior to processing.

3.1 Single-Phase Phenol Wash

A. Materials and Methods

The single-phase phenol wash and other wash solutions are described in Example 1 and 2. 1.5ml of solution A was added to a dried 10mm x 10mm piece of dry solid medium containing approximately 0.1 ml of dried human blood, and the solution was mixed using a standard laboratory mixer and incubated at 37°C for 30 minutes. The solution A was then removed by aspiration and fresh solution A added. Treatments with solution A were repeated until all the heme color disappeared from the dry solid medium.

Next, the samples were washed five times with solution B for two minutes each, then twice with solution C, also for about two minutes each. Between each wash, the medium sample was subjected to centrifugal stripping. For this the medium was briefly spun in a small microfuge tube in which a hole had been pierced and which had been nested inside a larger microfuge tube. The medium was then dried under vacuum or, alternatively, by centrifugal stripping. Following the processing steps the samples that initially were black after application of the blood and subsequent drying, were white.

**3.2 Digestion of Samples Stored on Dry Solid Medium
Using Restriction Enzymes**

A. Material

Restriction enzyme Eco R1 was used in buffers supplied by Boehringer Mannheim.

B. Method

The washed dry solid medium was moistened with 50 µl of restriction enzyme buffer containing an excess of restriction enzyme. For digestions with the restriction enzyme Eco R1, 60 units of enzyme were added. To ensure complete wetting, the medium was wet in the buffer, centrifugally stripped, and re-moistened with the buffer and enzyme mix. Digestions proceeded for 2.5 hours at 37°C:

The restricted DNA was stripped from the medium by first centrifugally stripping the medium and collecting the stripped fluid. DNA was then further removed by washing the solid medium with 25 µl of 7.5M ammonium acetate, followed by a wash with 25 µl of 2.5M ammonium acetate. At each wash step the medium was subjected to centrifugal stripping in order to maximize recovery of the fluids. The fluids from the wash steps were combined in a final volume of about 100 µl. The DNA was precipitated from the collected fluid by adding 250 µl of ethanol, and air-drying the final pellet. The pellet was resuspended in 20 µl of water, and 10 µl of the resuspended pellet was used in gel electrophoresis.

3.3 Gel Electrophoresis

A. Conditions for Gel Electrophoresis

Digestion products were electrophoresed in a 1.5% agarose gel prepared in Tris-Acetate (composition was 0.01 M Tris, 0.005M sodium acetate, 0.5M EDTA adjusted to pH 7.8 with acetic acid) at 50V, 80 mA for two hours, after which the gel was stained with ethidium bromide and photographed. (See Figure 3).

3.4 Results

To determine if blood samples stored on media of the invention for extended periods of time could be digested with restriction enzymes, samples of cellulose-based dry solid medium to which blood had been added 19 months previously, 11 months previously, or two weeks previously were processed and then digested with Eco R1. Figure 3 contains a photograph of the ethidium staining pattern and reveals a smearing pattern characteristic of an Eco R1 digest of human DNA. Thus, DNA stored on the medium for at least 19 months is digestible with restriction endonucleases.

EXAMPLE 4 **Inactivation of Herpes Simplex Virus Type I and other microorganisms, by the Dry Solid Medium**

In these experiments dry solid medium prepared according to the invention was tested for its ability to inactivate herpes simplex virus, type I (HSV). HSV-type I

was chosen because it is relatively resistant to inactivation and is transmissible through blood and other bodily fluids.

4.1 Isolation of HSV Virus

A. Materials and Method

A recent clinical isolate of HSV type I recovered from an eye lesion was grown to high titer ($>10^8$ plaque forming units/ml) in tissue culture flasks of Hep2 epithelial and MRC-5 fibroblast cells, harvested off the flasks, and sonicated to release intracellular virus. Viral particles were concentrated by high-speed centrifugation of a clarified supernatant of the sonicate and were resuspended in viral transport medium (VTM) containing 0.2M sucrose in a 0.02M phosphate buffer (pH 7.6), 10% fetal calf serum, and antibiotics.

4.2 Application of Viral Particles to the Dry Solid Medium and Subsequent Recovery

For experiment I of Example 4, the crude viral preparation was diluted 1:10 in either VTM or in fresh, heparinized blood. In 10 μ l sample of the dilution was tested in duplicate on both untreated 10 mm x 10 mm pieces of untreated cellulose based paper and also on 10 mm x 10mm square pieces of dry solid medium prepared according to the invention. After application of virus, the squares were supported in air by fine forceps, and after the appropriate time interval, the virus was eluted from the squares by vigorous agitation in 1 ml of MRC-5 maintenance medium (MM) (Eagles MEM based medium with Earle's salts) containing 2% fetal calf serum.

In experiment II of Example 4, a stock virus was taken from storage at -70°C and diluted 1:4 in citrated blood.

4.3 Assaying viral infectivity

A. Material and Method

5 The elute was tested for infectivity using a fluorescent focus assay. Samples were diluted 1:100 in MM, and 0.2 ml of the dilution was then added to a well of MRC-5 fibroblasts in a 48-well cluster tray. After a 45 minute incubation at 37°C, the sample was replaced with 0.5ml MM and the tray was incubated overnight at 37°C in the presence of 5% CO₂. Cells were then fixed, stained with fluorescein-conjugated
10 antibody to HSV, and the number of fluorescent foci was counted under a reverse-stage fluorescent microscope.

4.4 Results and Discussion

15 HSV type 1 viral particles were added either to untreated cellulose based paper or to cellulose based paper treated according to the invention to produce the dry solid medium, and then eluted after varying lengths of time. In one experiment, the virus was stored in VTM, and in the second the virus was resuspended in blood. The results of the experiment are shown in Table 2. In both experiments, viral infectivity was
20 reduced to undetectable levels--in these conditions, greater than 99.5% inhibition--when virus was added to the dry solid medium, even when the viral particles were eluted immediately. Viruses in blood eluted from untreated cellulose based paper (CBP), in contrast, were only slightly, if at all, inhibited. A similar inhibitory effect on HSV infectivity was observed when the experiments were
25 performed with viruses recovered from a frozen stock.

The invention has also shown the inhibitory effect of the dry solid medium on growth of Staphylococcus aureus, Staphylococcus epidermidis and adventitious microorganisms in the environment.

Table 2. Infectivity of HSV Following Application on to Untreated cellulose based paper (CBP) or on to Dry Solid Medium.

| Treatment | Viral Titer | Percent Inhibition | | Viral Titer | Percent Inhibition |
|--|---|--------------------|-----------------|---|--------------------|
| | A. HSV in VTM | | B. HSV in Blood | | |
| Untreated (virus added directly to MM) | 1.9×10^7 | 0 | | | -- |
| Virus spotted On treatment CBP and Immediately Eluted into MM | $<5.0 \times 10^4$ (no virus detected) | >99.5 | | $<5 \times 10^4$ (no virus detected) | 99.5 |
| Virus spotted on untreated CBP and Immediately eluted into MM | 1.2×10^7 | 37 | | 9.8×10^6 | 48 |
| Virus spotted on treated CBP and eluted onto MM after 10 Minutes | $<5 \times 10^4$ (no virus detected) | >97 | | $<5 \times 10^4$ (no virus detected) | >97 |
| Virus spotted on untreated CBP and eluted into MM after 10 minutes | 1.8×10^6 | 90 | | 9.7×10^6 | 47.5 |

5

EXAMPLE 5

Method for treating the dry solid medium of the invention for use in standard analysis systems.

The dry solid medium of the invention, with or without components for subsequent analysis can also be used in standard assays of analytes for diagnostic purposes, e.g., in the Guthrie Test for phenylketonuria (PKU) and enzymic assays such as a test for galactosemia. Both of these tests are routinely carried out on newborn infants. Prior to analysis using such standard assay systems, it is preferable

to neutralize the SDS and EDTA on the dry solid medium containing a sample of blood before the analysis of such analytes by adding a "converter solution."

5.1 Dry Solid Medium Converter Solution

The dry solid medium converter solution works by binding the SDS and EDTA.

A. Materials and Methods

The dry solid medium converter solution includes the following mixture:

1. 577 mg Protamine sulphate (salmine) Sigma No-4380, lot 71 F-0037, is added to 7.69 ml water and shaken (to give 75 mg/ml).

This batch will be nominally 75 mg/ml before dialysis. This concentration is near to the solubility of the protamine. It dissolves slowly as a gluey turbid mass.

2. Dialysis: this is a clean-up precaution to assure that the material is essentially sterile and fully dissolved.

The gluey turbid mass is placed in a dialysis bag approximately 1.5 cm in diameter by 2 cm to 10 cm in length. Both ends of the bag are knotted tightly. The bag is then weighed and dropped into a 1 liter flask containing about 800 ml of 50 mM of magnesium acetate with chloroform and a stirring bar. The material is dialyzed in the flask, overnight, against the 800 ml of 50 mM magnesium acetate with an excess (approximately 5 ml) of chloroform present as a sterilizing agent. The protamine almost completely dissolves overnight giving a clear solution and few obvious small lumps of debris.

The weight of the bag increases:

Weight of bag before dialysis = 8.1 g

20 hour dialysis, 4° with CHCl₃ saturated fluid.

Weight of bag after dialysis = 8.67 g.

Thus, the concentration of protamine is now, nominally, 70 mg/ml. (Assuming
5 no losses through bag).

3. The bag was then punctured at the bottom, and the fluid collected and
centrifuged at 4000 rpm (approximately 2000 x g) for 10 minutes to remove debris:

4. 1 ml lots were stored at -80°C.

10 5. Prior to analysis, about 3 µl of the converter solution is applied to each
3 mm diameter disk of dry solid medium containing a sample of blood.

5.2 PKU Screening Procedure (Guthrie Test)

The Guthrie test is based on the stimulatory effect of phenylalanine on the
15 growth of Bacillus subtilis in the presence of β 2-thienylalanine growth inhibitor.
Disks of blood samples are placed on agar containing bacterial spores and the
inhibitor. Following incubation at 37°C for 16 to 18 hours, the diameter of the growth
around the disk is proportional to the concentration of phenylalanine. Higher than
normal levels in infants is indicative of phenylketonuria.

20 An advantage of using the dry solid medium for the Guthrie test is that the
disk of dry solid medium retains proteins and hemoglobin from the sample, leaving a
cleaner area around the disk and making the interpretation of the result easier. In fact,
samples of blood containing phenylalanine which were stored on the dry solid
medium consistently gave at least as strong bacterial growth rings as equivalent
25 samples on standard paper.

Also, because sufficient bacterial spores are used in a Guthrie test and the rate
of growth is so fast, the inhibition or killing of bacteria by reagents of the dry solid

medium which were proximal to the dry solid medium did not cause a problem for interpreting the results. Therefore, when using the dry solid medium it is not necessary to apply the converter solution to the disk prior to the test. However, it is an advantage to do this to remove an observable weak zone of growth inhibition.

5 **5.3 Screening for Galactosemia**

Galactosemia screening requires the use of active enzymes to assay for galactose and galactose phosphate. The main enzyme, β -galactose dehydrogenase, reduces NAD to NADH and this is observed spectrophotometrically.

10 This assay is severely inhibited by components of the composition of the dry solid medium, but the inhibition can be substantially eliminated by the application of converter solution to a sample of blood stored on the dry solid medium.

After addition of the converter solution, just prior to the enzymic assay, the assay has been observed to perform in the same way as it does with a sample of blood
15 on untreated cellulose based paper. Of course, the dry solid medium has the advantage of providing the benefits of pathogen killing and preservation of the sample compared to standard materials used.

All patents and publications in the specification are indicative of the level of ordinary skill in the art to which this invention pertains. All patents and publications
20 are herein incorporated by reference to the same extent as if each individual patent and publication was specifically and individually indicated by reference.

EXAMPLE 6: Polyester Material Swab Device for obtaining, storing, and analyzing genetic material utilizing the dry solid medium and methods thereof

5 A swab device utilizing a FTA coating on polyester (PET) material can be used to obtain, store and analyze various genetic material samples. Sampling of buccal areas and any other areas where samples would be swabbed can be performed with the PET material coated with FTA. Once the sample is obtained, then the sample can be subsequently analyzed. Elution of the genetic material must be performed to
10 remove the genetic material from the PET swab.

There are numerous embodiments of the swab device, but the preferred embodiment employing the FTA-coated PET material has a narrow rod or stick-like support in combination with the FTA-coated PET material, which is positioned adjacent to the support. The PET material can be a formed into a filter, a mesh or
15 woven bulb, depending upon the application of the swab device. Additionally, the FTA-coated PET material can be simply wrapped around a support such as a CEP swab.

The FTA coating can be applied directly to just the surface of the PET material or it can be applied in a manner that coats all individual fibers. Any way the
20 FTA coating is applied will provide similar results. The method of using the swab device is provided in detail herewith.

6.1. Materials and Methods:

- 25 1. Scrape inside of cheek with the FTA coated PET swab.
2. Air-dry the swab for thirty minutes.
3. Cut head of swab in half using a pair of scissors that have been
30 "flamed."

4. Add 1 mL of 0.5% SDS and ensure that the swab is covered and no air bubbles reside under the swab.
5. Leave for five minutes at room temperature.
- 5 6. Aspirate off the solution.
7. Add 1mL 0.5% SDS and ensure that the swab is covered and no air bubbles reside under the swab.
8. Leave for five minutes at room temperature.
- 10 9. Aspirate off the solution.
- 10 10. Add 1 mL TE-1 and again ensure that the swab is completely covered and no air bubbles lie under the swab.
- 15 11. Leave for five minutes at room temperature.
12. Aspirate off the solution.
13. Add 1 mL TE-1 and again ensure that the swab is completely covered and no air bubbles lie under the swab.
- 20 14. Leave for five minutes at room temperature.
15. Aspirate off the solution.
- 25 16. Add 1mL TE-1 and again ensure that the swab is completely covered and no air bubbles lie under the swab.
17. Leave for five minutes at room temperature.
18. Aspirate off the solution.
- 30 19. Apply 0.2 mL of sterile nuclease free water.
20. Place in 95° C water bath for fifteen minutes.
- 35 21. Spin at 12000g for two minutes.
22. Remove supernatant to a fresh, sterile eppendorf tube.
- 40 6.2. Results and Discussion:

The yields for recovered DNA are given below and were assessed using Oligreen.

| | Run 1: ng/ μ l | Run 2: ng/ μ l |
|---|--------------------|--------------------|
| 1 | 0.6 | 0.6 |
| 2 | 1.9 | 1.6 |
| 3 | 1.4 | 1 |
| 4 | 0.7 | 0.7 |
| 5 | 1.8 | 2.4 |
| 6 | 1 | 1.5 |

Although the yields appear low, DNA was recovered. To ensure a profile could be generated, 10 μ l of each sample were employed in our standard multiplex reaction. These generated complete profiles. The attached figure 5 shows an example of a complete profile.

A second batch of reactions was set up in single point PCRs amplifying a 1.3 kb fragment from the single locus B-globin. These reactions all employed 10 μ l of the DNA solutions, so varying quantities of starting material were employed in a 20 μ l reaction volume. Figure 5 shows the data generated.

The results of this series of extractions show that a swab generated from PET and FTA would be a good combination for both storing and isolating DNA from buccal scrapes. It would also be applicable to many other areas where samples would be swabbed and genetic material later analyzed.

These series of experiments illustrate the utility of FTA coating PET filter membrane for the collection and extraction of liquid DNA for amplification by PCR or multiplex profiling. An example of eluting FTA filter membrane other than glass microfiber is shown.

The invention has been described in an illustrative manner, and it is to be understood that the terminology that has been used is intended to be in the nature of words of description rather than of limitation.

Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within
5 the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

It will be apparent to one of ordinary skill in the art that many changes and modifications can be made in the invention without departing from the spirit or scope
10 of the appended claims.

REFERENCES

McCabe, E.R.B., et al., "DNA Microextraction From Blood Spots on Filter Paper
15 Blotters: Potential Screening Applications to Newborn Screening," Hum. Genet.
75:213-216 (1987)

Claims:

What is claimed is:

- 5 1. A swab device for obtaining and storing of a sample of genetic material, wherein said swab device includes a dry solid medium comprising:
 a support and a head portion, said head portion consisting essentially of a solid matrix for sorbing genetic material thereon;
 and
10 preserving means sorbed to said solid matrix for protecting the genetic material, applied to said solid matrix, from degradation.
2. The swab device as set forth in Claim 1, wherein said solid matrix is selected from the group consisting essentially of cellulose based material, hydrophilic polymers, synthetic hydrophilic polymers, polyester, polyamide,
15 carbohydrate polymers, polytetrafluoroethylene, fiberglass and porous ceramics.
3. The swab device as set forth in Claim 1 further including releasing means for releasing the genetic material from the solid matrix.
4. The swab device as set forth in Claim 3, wherein said releasing means is
20 further defined including heat releasing means for releasing the genetic material from said solid matrix upon application of heat.
5. A method of storing a sample of genetic material onto a swab device by
 sorbing genetic material on a swab and
 preserving and protecting the genetic material applied to the swab.
- 25 6. The method as set forth in Claim 5, including the further step of releasing the sorbed genetic material from the solid swab.
7. The method as set forth in Claim 6, wherein said releasing step further includes application of heat upon the solid swab.
8. The method as set forth in Claim 5, wherein the swab includes a preserving
30 means sorbed to the swab before the genetic material is sorbed thereto.

1/5




FIG. 1

BEST AVAILABLE COPY

SUBSTITUTE SHEET (RULE 26)

2/5





FIG. 2

BEST AVAILABLE COPY

SUBSTITUTE SHEET (RULE 26)

3/5

FAINT BANDS OF DNA FROM REPETITIVE SEQUENCES
VISIBLE ON ORIGINAL SUPERIMPOSED ON SEQUENCE SMEAR
RFLP



- (1) BLANK
- (2) IN SITU RESTRICTION
FROM 50 μ L -100 μ L OF BLOOD
VIRTUALLY 100% DNA RECOVERY
- (3) ATTEMPT TO WASH DNA OUT OF
FTA FAILS TO WORK
(SDS & PROTEINASE K)
- (4) MOLECULAR WT STANDARDS
- (5) 2nd ATTEMPT TO WASH DNA OUT OF
FTA (LONGER TREATMENT SDS &
PROT. K WORKS POORLY)

CONCLUDE THAT IN SITU RESTRICTION
IS ESSENTIAL FOR EFFICIENT REMOVAL
OF DNA FROM FTA MEDIUM FOR RFLP
ANALYSIS

FIG. 3

SUBSTITUTE SHEET (RULE 26)

BEST AVAILABLE COPY

4/5




FIG. 4

SUBSTITUTE SHEET (RULE 26)

BEST AVAILABLE COPY

5/5




FIG. 5

1

SEQUENCE LISTING

<110> BURGOYNE, LEIGH
BUTT, NEIL
SMITH, MARTIN

<120> DRY SOLID MEDIUM FOR STORAGE AND ANALYSIS OF GENETIC MATERIAL

<130> 45858/56060-C-CIP-C2-CIP

<140> 09/805,326

<141> 2001-03-13

<150> 09/335,656

<151> 1999-06-18

<150> 08/979,833

<151> 1997-11-26

<150> 08/480,135

<151> 1995-06-07

<150> 08/159,104

<151> 1993-11-30

<150> 07/671,859

<151> 1991-05-29

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 1

tgactgagta caaactggtg gtg

23

<210> 2

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 2

ctctatggtg ggatcatatt ca

22

<210> 3

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 3

tgggctggaa tggaaaggaa tgcaaac

27

<210> 4

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 4

tccattcgat tccatttttt tcgagaa

27

<210> 5

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 5

gaatgtatta gaatgtaatg aacttta

27

<210> 6

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 6

ttccattcca ttccattcct ttccttt

27

<210> 7

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 7

gtgctgcagg tgtaaacttg taccag

26

3

<210> 8

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 8

cacggatccg gtagcagcgg tagagttg

28

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 2002/072870 A3

(51) International Patent Classification⁷: **C12Q 1/68**

(21) International Application Number:
PCT/US2002/007546

(22) International Filing Date: 13 March 2002 (13.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/805,326 13 March 2001 (13.03.2001) US

(71) Applicant: WHATMAN, INC. [US/US]; 200 Wells Avenue, Newton, MA 02459-3304 (US).

(72) Inventors: BURGOYNE, Leigh, Alexander; 18 Broughton Avenue, A-5062 Mitcham (AU). SMITH, Martin; 127 Browne Street, Brookline, MA 02146 (US). BUTT, Neil, James; 15 Petworth Street, Cambridge CB2 2LY (GB).

(74) Agents: HAZZARD, Lisa, Swiszczy et al.; Edwards & Angell, LLP, P.O. Box 9169, Boston, MA 02209 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
1 April 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DRY SOLID MEDIUM FOR STORAGE AND ANALYSIS OF GENETIC MATERIAL

(57) Abstract: The present invention provides for device for obtaining and storing genetic material. The device has a support and a head portion. The head portion is composed of a solid matrix for sorbing genetic material and a preserving mechanism for the protection of genetic material from degradation. Additionally, the present invention provides for a method of storing a sample of genetic material onto the swab device. In the preferred embodiment, the present invention utilizes polyester material as the solid matrix.

INTERNATIONAL SEARCH REPORT

PCT/US 02/07546

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | WO 90 03959 A (UNIV SOUTHERN AUSTRALIA) 19 April 1990 (1990-04-19) abstract; claims 1-23; examples 1-3 --- | 1-8 |
| X | US 5 985 327 A (BURGOYNE L.A.) 16 November 1999 (1999-11-16) abstract; claims 1-17; examples 1-3 column 2, line 20-34 --- | 1-8 |
| X | US 5 807 527 A (BURGOYNE L.A.) 15 September 1998 (1998-09-15) abstract; claims 1-17; examples 1-3 column 2, line 16-31 --- -/-- | 1-8 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

28 October 2003

Date of mailing of the international search report

05/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Barz, W

INTERNATIONAL SEARCH REPORT

PCT/US 02/07546

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | US 5 496 562 A (BURGOYNE L.A.) 5 March 1996 (1996-03-05) cited in the application abstract; claims 1-16; examples 1-3 column 2, line 15-29 --- | 1-8 |
| X | US 5 976 572 A (BURGOYNE L.A.) 2 November 1999 (1999-11-02) abstract; claims 1-20; examples 1-5 column 2, line 57 -column 4, line 15 --- | 1-8 |
| X | WO 96 39813 A (FLINDERS TECHNOLOGIES PTY LTD) 19 December 1996 (1996-12-19) abstract; claims 1-55 page 4, line 11 -page 7, line 4 --- | 1-8 |
| X | US 5 756 126 A (BURGOYNE L.A.) 26 May 1998 (1998-05-26) abstract; claims 1-31; examples 1-3 --- | 1-8 |
| X | US 5 972 386 A (BURGOYNE L.A.) 26 October 1999 (1999-10-26) abstract; claims 1-17; examples 1-5 --- | 1-8 |
| X | US 5 939 259 A (HARVEY M.A. ET AL.) 17 August 1999 (1999-08-17) abstract; figure 2; examples 1-6 column 2, line 46 -column 3, line 63 claims 1-12 --- | 1-8 |
| X | WO 00 53807 A (WHATMAN INC) 14 September 2000 (2000-09-14) abstract; claims 1-38; examples 1-8 --- | 1-8 |
| A | RAMANUJAM R. ET AL.: "STABILIZATION OF NUCLEIC ACIDS IN WHOLE BLOOD: AN ALTERNATIVE TO GUTHRIE CARDS" BIOTECHNIQUES, vol. 15, no. 5, 1 November 1993 (1993-11-01), pages 825-826, 828, XP002034861 ISSN: 0736-6205 the whole document --- | 1-8 |
| A | DEVANGE PANTELEEFF D. ET AL.: "RAPID METHOD FOR SCREENING DRIED BLOOD SAMPLES ON FILTER PAPER FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 DNA" JOURNAL OF CLINICAL MICROBIOLOGY, vol. 37, February 1999 (1999-02), pages 350-353, XP002927510 ISSN: 0095-1137 abstract ----- | 1-8 |

INTERNATIONAL SEARCH REPORT

PCT/US 02/07546

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9003959 | A | 19-04-1990 | WO 9003959 A1 | 19-04-1990 |
| | | | CA 2000192 A1 | 05-04-1990 |
| | | | US 5496562 A | 05-03-1996 |
| | | | US 6294203 B1 | 25-09-2001 |
| | | | US 6322983 B1 | 27-11-2001 |
| | | | US 6447804 B1 | 10-09-2002 |
| | | | US 2002146696 A1 | 10-10-2002 |
| | | | US 5985327 A | 16-11-1999 |
| US 5985327 | A | 16-11-1999 | US 5807527 A | 15-09-1998 |
| | | | US 5496562 A | 05-03-1996 |
| | | | US 6322983 B1 | 27-11-2001 |
| | | | WO 9003959 A1 | 19-04-1990 |
| | | | CA 2000192 A1 | 05-04-1990 |
| | | | US 6294203 B1 | 25-09-2001 |
| | | | US 6447804 B1 | 10-09-2002 |
| | | | US 2002146696 A1 | 10-10-2002 |
| | | | US 5756126 A | 26-05-1998 |
| | | | US 5976572 A | 02-11-1999 |
| US 5807527 | A | 15-09-1998 | US 5496562 A | 05-03-1996 |
| | | | US 6322983 B1 | 27-11-2001 |
| | | | US 5985327 A | 16-11-1999 |
| | | | US 6294203 B1 | 25-09-2001 |
| | | | US 6447804 B1 | 10-09-2002 |
| | | | US 5756126 A | 26-05-1998 |
| | | | US 2002146696 A1 | 10-10-2002 |
| | | | US 5976572 A | 02-11-1999 |
| US 5496562 | A | 05-03-1996 | US 6294203 B1 | 25-09-2001 |
| | | | US 6322983 B1 | 27-11-2001 |
| | | | US 6447804 B1 | 10-09-2002 |
| | | | US 5756126 A | 26-05-1998 |
| | | | US 5807527 A | 15-09-1998 |
| | | | US 2002146696 A1 | 10-10-2002 |
| | | | US 5976572 A | 02-11-1999 |
| | | | US 5985327 A | 16-11-1999 |
| | | | WO 9003959 A1 | 19-04-1990 |
| | | | CA 2000192 A1 | 05-04-1990 |
| US 5976572 | A | 02-11-1999 | US 5756126 A | 26-05-1998 |
| | | | US 5496562 A | 05-03-1996 |
| | | | US 6294203 B1 | 25-09-2001 |
| | | | US 6447804 B1 | 10-09-2002 |
| | | | US 2002146696 A1 | 10-10-2002 |
| | | | AU 691114 B2 | 07-05-1998 |
| | | | AU 5887696 A | 30-12-1996 |
| | | | WO 9639813 A1 | 19-12-1996 |
| | | | CN 1192648 A | 09-09-1998 |
| | | | EP 0849992 A1 | 01-07-1998 |
| | | | US 6322983 B1 | 27-11-2001 |
| | | | US 5807527 A | 15-09-1998 |
| | | | US 5985327 A | 16-11-1999 |
| WO 9639813 | A | 19-12-1996 | US 5756126 A | 26-05-1998 |
| | | | US 5972386 A | 26-10-1999 |
| | | | AU 691114 B2 | 07-05-1998 |
| | | | AU 5887696 A | 30-12-1996 |

INTERNATIONAL SEARCH REPORT

PCT/US 02/07546

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9639813 | A | | WO 9639813 A1 | 19-12-1996 |
| | | | CN 1192648 A | 09-09-1998 |
| | | | EP 0849992 A1 | 01-07-1998 |
| | | | US 6294203 B1 | 25-09-2001 |
| | | | US 6447804 B1 | 10-09-2002 |
| | | | US 2002146696 A1 | 10-10-2002 |
| | | | US 5976572 A | 02-11-1999 |
| <hr/> | | | | |
| US 5756126 | A | 26-05-1998 | US 5496562 A | 05-03-1996 |
| | | | AU 691114 B2 | 07-05-1998 |
| | | | AU 5887696 A | 30-12-1996 |
| | | | WO 9639813 A1 | 19-12-1996 |
| | | | CN 1192648 A | 09-09-1998 |
| | | | EP 0849992 A1 | 01-07-1998 |
| | | | US 6294203 B1 | 25-09-2001 |
| | | | US 6447804 B1 | 10-09-2002 |
| | | | US 2002146696 A1 | 10-10-2002 |
| | | | US 5976572 A | 02-11-1999 |
| | | | US 6322983 B1 | 27-11-2001 |
| | | | US 5807527 A | 15-09-1998 |
| | | | US 5985327 A | 16-11-1999 |
| <hr/> | | | | |
| US 5972386 | A | 26-10-1999 | AU 691114 B2 | 07-05-1998 |
| | | | AU 5887696 A | 30-12-1996 |
| | | | WO 9639813 A1 | 19-12-1996 |
| | | | CN 1192648 A | 09-09-1998 |
| | | | EP 0849992 A1 | 01-07-1998 |
| | | | US 6447804 B1 | 10-09-2002 |
| <hr/> | | | | |
| US 5939259 | A | 17-08-1999 | US 6168922 B1 | 02-01-2001 |
| <hr/> | | | | |
| WO 0053807 | A | 14-09-2000 | AU 6048199 A | 28-09-2000 |
| | | | EP 1173623 A1 | 23-01-2002 |
| | | | WO 0053807 A1 | 14-09-2000 |
| | | | US 2001007746 A1 | 12-07-2001 |
| | | | US 2001000149 A1 | 05-04-2001 |

